DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Enbrel (Etanercept) - Published Studies

 
 



Enbrel Related Published Studies

Well-designed clinical trials related to Enbrel (Etanercept)

High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). [2011.10]

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. [2011.07]

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. [2011.06]

Etanercept compared to intraarticular corticosteroid injection in rheumatoid arthritis: double-blind, randomized pilot study. [2011.06]

Efficacy and safety of etanercept in moderate-to-severe asthma: a randomised, controlled trial. [2011.06]

Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). [2011.05]

Post-approval trials of new medicines: widening use or deepening knowledge? Analysis of 10 years of etanercept. [2011.05]

Combination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trial. [2011.05]

Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. [2011.04]

Etanercept as adjunctive treatment for acute Kawasaki disease: study design and rationale. [2011.03]

Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. [2011.02]

The ACCEPT study: ustekinumab versus etanercept in moderate-to-severe psoriasis patients. [2011.01]

TNF-alpha antagonism with etanercept decreases glucose and increases the proportion of high molecular weight adiponectin in obese subjects with features of the metabolic syndrome. [2011.01]

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. [2011.01]

[A multicenter, double-blind, randomized, placebo-controlled clinical trial of etanercept treatment of Chinese patients with active ankylosing spondylitis]. [Article in Chinese] [2011]

Cost utility analysis based on a head-to-head Phase 3 trial comparing ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: a Canadian perspective. [2011]

Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. [2011]

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis. [2011]

Patient-reported outcomes in pediatric patients with psoriasis undergoing etanercept treatment: 12-week results from a phase III randomized controlled trial. [2011]

Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. [2010.12]

Intermittent etanercept therapy in pediatric patients with psoriasis. [2010.11]

Long-term etanercept in pediatric patients with plaque psoriasis. [2010.11]

Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. [2010.11]

A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. [2010.09]

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. [2010.08]

Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis. [2010.08]

The role of etanercept on the expression of markers of T helper 17 cells and their precursors in skin lesions of patients with psoriasis vulgaris. [2010.07]

The effect of etanercept on suppression of the systemic inflammatory response in chronic hemodialysis patients. [2010.06]

Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. [2010.06]

Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. [2010.06]

[Intermittent use of etanercept in psoriasis] [2010.05]

Treatment of hidradenitis suppurativa with etanercept injection. [2010.05]

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. [2010.05]

Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. [2010.04]

Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. [2010.03]

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. [2010.03]

Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. [2010.02.02]

Tumor necrosis alpha-blocking agent (etanercept): a triple blind randomized controlled trial of its use in treatment of sciatica. [2010.02]

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. [2010.01.14]

Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. [2010.01]

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. [2010.01]

Effect of etanercept in polymyalgia rheumatica: a randomized controlled trial. [2010]

Long-term etanercept in pediatric patients with plaque psoriasis. [2010]

Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. [2010]

Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. [2010]

Efficacy and safety of etanercept in children and adolescents aged > or = 8 years with severe plaque psoriasis. [2010]

Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. [2010]

Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. [2010]

Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. [2009.11]

The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. [2009.10]

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. [2009.08]

Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. [2009.07.16]

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study. [2009.07]

Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. [2009.07]

Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. [2009.07]

Randomized, double-blind, placebo-controlled, dose-response, and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica. [2009.05]

Effects of etanercept on urine neopterin levels in patients with psoriasis in a controlled, open-label study. [2009.04]

A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. [2009.04]

Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. [2009.03]

Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. [2009.03]

Once-weekly administration of etanercept 50 mg improves patient-reported outcomes in patients with moderate-to-severe plaque psoriasis. [2009]

A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. [2008.12]

Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. [2008.11.01]

Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension. [2008.11]

Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. [2008.10]

Lack of efficacy of etanercept in Sjogren syndrome correlates with failed suppression of tumour necrosis factor alpha and systemic immune activation. [2008.10]

Etanercept in the treatment of palmoplantar pustulosis. [2008.10]

Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. [2008.08.02]

Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: the ADORE trial. [2008.08]

Evaluating the tolerability and efficacy of etanercept compared to triamcinolone acetonide for the intralesional treatment of keloids. [2008.08]

Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. [2008.08]

Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. [2008.07]

The role of a soluble TNFalpha receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial. [2008.07]

Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. [2008.07]

Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. [2008.06]

Patient-reported outcomes and health-care resource utilization in patients with psoriasis treated with etanercept: continuous versus interrupted treatment. [2008.05]

Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. [2008.05]

Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. [2008.05]

A double-blind placebo controlled trial of etanercept in patients with giant cell arteritis and corticosteroid side effects. [2008.05]

Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. [2008.04]

Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. [2008.03]

Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. [2008.03]

The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. [2008.02]

Etanercept treatment for children and adolescents with plaque psoriasis. [2008.01.17]

The combination of etanercept and methotrexate increases the effectiveness of treatment in active psoriasis despite inadequate effect of methotrexate therapy. [2008]

Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. [2007.12]

Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. [2007.12]

The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: a systematic literature review. [2007.11]

Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. [2007.11]

A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. [2007.09.15]

The effect of etanercept on cardiac transplant recipients: a study of TNFalpha antagonism and cardiac allograft hypertrophy. [2007.08.27]

A double-blind, placebo-controlled, dose-response pilot study evaluating intradiscal etanercept in patients with chronic discogenic low back pain or lumbosacral radiculopathy. [2007.07]

A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. [2007.07]

Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. [2007.07]

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. [2007.06]

Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. [2007.06]

A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. [2007.04]

Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. [2007.02]

Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. [2007.01]

Etanercept and efalizumab treatment for high-need psoriasis. Effects and side effects in a prospective cohort study in outpatient clinical practice. [2007]

Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. [2006.12]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014